CD274 and non-small cell lung carcinoma: In line with this notion, it was found that KRAS mutation was associated with an inflammatory TME and tumor immunogenicity, leading to higher response of patients to anti-PD-1/PD-L1 immunotherapy in NSCLC patients (98).